相关临床试验
6
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
2
33.3%
招募中
2
33.3%
终止
2
33.3%
暂无批准数据
- Novartis executives project the radioligand therapy market could reach at least $10 billion for the company alone, with industry leaders expecting tens of billions in total market value. - Theranostic radiopharmaceuticals, which combine diagnostic imaging with targeted radiation therapy, are emerging as "the future" of the field by enabling precise patient selection and treatment monitoring. - Major pharmaceutical companies including Bristol Myers Squibb, Eli Lilly, and AstraZeneca have invested billions in radiopharmaceutical acquisitions, with venture financing reaching a record $408 million in 2023. - Industry experts identify supply chain bottlenecks, imaging capacity constraints, and specialized manufacturing requirements as key challenges that must be addressed before widespread market expansion.
- Myricx Bio has appointed Mohit Rawat as CEO, bringing extensive biopharma experience from Fusion Pharmaceuticals, which was acquired by AstraZeneca for $2.4 billion in 2024. - The company is developing a novel class of ADC payloads based on N-myristoyltransferase inhibitors to address payload resistance and toxicity issues affecting current ADC therapies. - Following a £90 million Series A financing, Myricx expects to initiate human clinical trials with its lead NMTi-ADC candidate in 2026. - Current ADCs face significant challenges with retreatment showing >50% reduction in objective response rates and >50% of leading ADCs requiring treatment interruptions or dose reductions due to adverse effects.
- Radiopharmaceuticals are emerging as a powerful precision medicine approach in oncology, with Novartis leading the market through FDA-approved therapies Lutathera and Pluvicto generating over $2.1 billion in 2024. - Major pharmaceutical companies including AstraZeneca, Bristol Myers Squibb, Eli Lilly, and Bayer are aggressively entering the space through acquisitions and pipeline development, targeting a market projected to reach $16 billion by 2033. - Innovation is focused on advancing from beta to more powerful alpha-emitting isotopes like actinium-225, improving targeting mechanisms, expanding into earlier treatment settings, and exploring combination therapies to enhance efficacy.
- Biopharma M&A activity totaled $79.4 billion in 2024, representing approximately half of 2023's total value, though deal volume saw a slight increase when excluding four mega-deals from the previous year. - Vertex Pharmaceuticals led the year's largest acquisition with its $4.9 billion purchase of Alpine Immune Sciences, followed by Gilead's $4.3 billion acquisition of CymaBay and Eli Lilly's $3.2 billion purchase of Morphic. - Oncology remained the dominant therapeutic area for dealmaking, accounting for more than a third of all 2024 biopharma transactions by both number and total value, with approximately $90 billion in cancer-focused deals. - Deal activity shifted toward earlier-stage assets and smaller transactions as buyers digested large previous acquisitions and the supply of late-stage and marketed assets diminished.
• GLP-1 receptor agonists like semaglutide and tirzepatide showed potential beyond diabetes and weight loss, including cardiovascular and mental health benefits. • CRISPR gene editing entered the market with Casgevy for sickle cell disease and β-thalassemia, though uptake has been slow due to complex treatment requirements. • Protein-folding algorithms developed by Nobel laureates revolutionized biochemical research and found applications in pharmaceutical drug discovery. • Antibody-drug conjugates (ADCs) saw major investment, with firms focusing on novel linker chemistries to enhance their efficacy and target specificity.
